Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
 1 a 20 de 100 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Alijotas-Reig J, Esteve-Valverde E. Embarazo y enfermedades autoinmunitarias. Med Clin (Barc) 2017;148:161-3. [Ref.ID 101400]
2. Cita con resumen
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao L-L, MIao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel J-F, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P, for the UNITI-IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2016;375:1946-60. [Ref.ID 100991]
3. Cita con resumen
Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, Munro R, McLaren J, McRorie E, Packham J, Buckley CD, Harvie J, Taylor P, Choy E, Pitzalis C, McInnes IB. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 2016;388:239-47. [Ref.ID 100631]
4. Cita con resumen
French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-a agents. Drug Saf 2016;39:199-208. [Ref.ID 100140]
5.Enlace a cita original Cita con resumen
Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, on behalf of the network of French pharmacovigilance centres, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Duman MK, Meister R, Schaefer C. Pregnancy outcome after TNF-a inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39. [Ref.ID 99609]
6. Cita con resumen
Anónimo. Védolizumab. Prescrire 2015;35:263-4. [Ref.ID 99125]
7. Cita con resumen
Anónimo. Drugs for rheumatoid arthritis. Med Lett Drugs Ther 2014;56:127-32. [Ref.ID 98445]
8. Cita con resumen
Anónimo. Vedolizumab (Entyvio) for inflammatory bowel disease. Med Lett Drugs Ther 2014;56:86-8. [Ref.ID 98222]
9. Cita con resumen
Anónimo. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis. Med Lett Drugs Ther 2014;56:10-2. [Ref.ID 97221]
11. Cita con resumen
Simon PC, Vallano A. Fármacos que inhiben el factor de necrosis tumoral alfa y embarazo. Med Clin (Barc) 2013;141:257-9. [Ref.ID 96078]
12.Tiene citas relacionadas
Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 2013;369:754-62. [Ref.ID 96021]
13.Tiene citas relacionadas
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A, for the GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21. [Ref.ID 96018]
14.Tiene citas relacionadas
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, Van Assche G, Axler J, Kim H-J, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A, for the GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710. [Ref.ID 96017]
15. Cita con resumen
Sandborn WJ, Gasink C, Gao L-L, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJS, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG, for the CERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367:1519-28. [Ref.ID 93891]
16.Tiene citas relacionadas
Dixon W, Felson DT. Is anti-TNF therapy safer than previously throught?. JAMA 2011;306:2331. [Ref.ID 91687]
17.Tiene citas relacionadas Cita con resumen
Grijalva CG, Chen L, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of tumor necrosis factor-alfa antagonists and the risk of hospitalization for infection in patients with autoimmune diseses. JAMA 2011;306:2331-9. [Ref.ID 91686]
18. Cita con resumen
Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M, for the REAL Study Group. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the registry of Japanese rheumatoid arthritis patients for longterm safety. J Rheumatol 2011;38:1258. [Ref.ID 90816]
19. Cita con resumen
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-57. [Ref.ID 88168]
20. Cita con resumen
Anónimo. So, what exactly is a cytokine?. Drug Ther Bull 2009;47:89-91. [Ref.ID 86611]
Seleccionar todas
 
 1 a 20 de 100 siguiente >>